Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Inclusion Criteria

• Patients must have newly diagnosed or recurrent (post surgery) histologically or cytologically proven cholangiocarcinoma.
• Patients can have solitary, multifocal unilobar, or bilobar disease without evidence of extrahepatic involvement. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >10 mm with spiral computed tomography (CT) scan or magnetic resonance imaging (MRI).
• Age >18 years
• Life expectancy of greater than 3 months based on physician judgment
• Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 (Karnofsky 50%)
• No prior chemotherapy or radiation treatment for cholangiocarcinoma
• Childs-Pugh score A or Childs-Pugh score B without portal vein thrombus
• Lung shunting that predicts lung dose to be 8.0

Exclusion Criteria

• Patients receiving any other investigational agents
• Patients with extrahepatic disease
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study because TheraSpheres are radioactive and radiation is a known agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TheraSpheres, breastfeeding should be discontinued if the mother is treated with TheraSpheres.
• Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy. In addition, antiretrovirals are known radiation sensitizers and could dramatically increase the risk of fulminant hepatic failure. Therefore, HIV-positive patients are excluded from the study because of possible lethal side effects.
• Bulk disease (tumor volume > 70% of the target liver volume, or tumor nodules too numerous to count)
• Aspartic transaminase (AST) or alanine transaminase (ALT) > 5 times upper limit of normal (ULN)
• Bilirubin > 2 mg/dL
• Child-Pugh C Liver Cirrhosis
• Tumor volume > 50% combined with an albumin < 3 g/dL
• Complete occlusion of main portal vein causing portal hypertension